Short answer
Pfizer Inc (PFE) filed its Q3 2026 10-Q quarterly report on Nov 3, 2026 for the quarter ended Sep 27, 2026. Quarterly revenue was $16.6B (down 0.4% year over year) with net income of $3.2B.
Q3 2026 key financials · XBRL
- Revenue
- $16.6B
- −0.4% YoY · +10.3% QoQ
- Net income
- $3.2B
- −8.5% YoY · +1412.1% QoQ
- EPS (diluted)
- $0.56
- −9.7% YoY · +1500.0% QoQ
Source: XBRL data from the Pfizer Inc (PFE) Q3 2026 10-Q on SEC EDGAR. USD.
Pfizer Inc Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $16.6B, down $71M YoY from $16.7B, operationally down $57M
- Q3 cost-of-sales margin 24.3% vs 25.0% YoY, pretax income $3.4B vs $3.3B
- Best product: Padcev revenue $720M, up 55% operationally; worst: Paxlovid $449M, down 63%
- Nine-month operating cash flow $8.825B vs $6.356B; no share repurchases, $1.875B ViiV proceeds
- Headwinds: 2026 exclusivity expiries expected to reduce revenue by approximately $1.1B, with pricing and regulatory pressures continuing
Risk Factors
- Patent exclusivity expirations: 2026 revenue impact expected at approximately $1.1 billion
- IRA pricing pressure: Eliquis Medicare maximum fair price effective January 1, 2026
- 340B compliance exposure: HHS pilot program for Eliquis, Ibrance and Xtandi expected January 2027, subject to litigation
- Tariff risk: Section 232 duties up to 100%, with Pfizer’s applicable rate zero until January 20, 2029
- Product performance risk: Prevnar revenue down 10% operationally in the quarter amid lower vaccination rates and U.S. adult share erosion
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Pfizer Inc quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.